Cited by 793Immune cells in cancerImmunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.

A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4+CD25+Foxp3+ T Cells

Open access

Hoechst, Bastian, Ormandy, Lars A., Ballmaier, Matthias, Lehner, Frank, Krüger, Christine, Manns, Michael P., Greten, Tim F., Korangy, Firouzeh·2008·Gastroenterology

DOI 10.1053/j.gastro.2008.03.020

Open this paper in CoChat — free account Open PDF

Abstract

Background & aims Several studies have shown that development of hepatocellular carcinoma (HCC) generates a number of immune suppressive mechanisms in these patients. Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of cells that have been shown to inhibit T-cell responses in tumor-bearing mice, but little is known about these cells in humans owing to a lack of specific markers. In this study, we have investigated the frequency and function of a new population of MDSC denoted here as CD14(+)HLA-DR(-/low) in HCC patients. We have also identified a novel, MDSC-mediated immune regulatory pathway in these patients.Methods We have directly isolated and characterized MDSCs for phenotype and function from peripheral blood (n = 111) and tumor (n = 12) of patients with HCC.Results The frequency of CD14(+)HLA-DR(-/low) cells in peripheral blood mononuclear cells (PBMC) from HCC patients was significantly increased in comparison with healthy controls. CD14(+) HLA-DR(-/low) cells were unable to stimulate an allogeneic T-cell response, suppressed autologous T-cell proliferation, and had high arginase activity, a hallmark characteristic of MDSC. Most important, CD14(+)HLA-DR(-/low) cells from HCC patients induced a CD4(+)CD25(+)Foxp3(+) regulatory T-cell population when cocultured with autologous T cells.Conclusion CD14(+)HLA-DR(-/low) cells are a new population of MDSC increased in blood and tumor of HCC patients. We propose a new mechanism by which MDSC exert their immunosuppressive function, through the induction of CD4(+)CD25(+)Foxp3(+) regulatory T cells in cocultured CD4(+) T cells. Understanding the mechanism of action of MDSC in HCC patients is important in the design of effective immunotherapeutic protocols.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2008.03.020

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Regulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature reviews. Immunology · doi:10.1038/nri1806 · Cited by 2,135
Induction of Interleukin 10–Producing, Nonproliferating Cd4+ T Cells with Regulatory Properties by Repetitive Stimulation with Allogeneic Immature Human Dendritic Cells
Jonuleit, H., Schmitt, E., Schuler, G., Knop, J., & Enk, A. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.9.1213 · Cited by 1,538
Immune surveillance of tumors
Swann, J. B., & Smyth, M. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31405 · Cited by 1,518
Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host
Huang, B., Pan, P.-Y., Li, Q., Sato, A. I., Levy, D. E., Bromberg, J., Divino, C. M., & Chen, S.-H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1299 · Cited by 1,435
Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,340
Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses
Rodriguez, P. C., Quiceno, D. G., Zabaleta, J., Ortiz, B., Zea, A. H., Piazuelo, M. B., Delgado, A., Correa, P., Brayer, J., Sotomayor, E. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0465 · Cited by 1,276
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer
Nagaraj, S., Gupta, K., Писарев, В. М., Kinarsky, L., Sherman, S., Kang, L., Herber, D. L., Schneck, J. P., & Gabrilovich, D. I. (2007) · Nature Medicine · doi:10.1038/nm1609 · Cited by 1,176
Intratumoral Balance of Regulatory and Cytotoxic T Cells Is Associated With Prognosis of Hepatocellular Carcinoma After Resection
Gao, Q., Qiu, S., Fan, J., Zhou, J., Wang, X., Xiao, Y., Xu, Y., Li, Y., & Tang, Z. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4565 · Cited by 1,134
Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients.
Schmielau, J., & Finn, O. J. (2001) · PubMed · Cited by 867

Show all 31 references

Sorted by citations

Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Immunotherapies for hepatocellular carcinoma
Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand‐Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,777
The role of myeloid cells in the promotion of tumour angiogenesis
Murdoch, C., Muthana, M., Coffelt, S. B., & Lewis, C. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2444 · Cited by 1,642
Systemic immunity in cancer
Hiam-Galvez, K. J., Allen, B. M., & Spitzer, M. H. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00347-z · Cited by 1,400
Advances in immunotherapy for hepatocellular carcinoma
Sangro, B., Sarobe, P., Hervás-Stubbs, S., & Melero, I. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00438-0 · Cited by 1,306
Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects
Li, C., Jiang, P., Wei, S., Xu, X., & Wang, J. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01234-1 · Cited by 972
Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
Ko, J. S., Zea, A. H., Rini, B. I., Ireland, J. L., Elson, P. J., Cohen, P. A., Golshayan, A., Rayman, P. A., Wood, L. S., García, J. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1332 · Cited by 861
NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis
Ma, C., Kesarwala, A. H., Eggert, T., Medina-Echeverz, J., Kleiner, D. E., Jin, P., Stroncek, D. F., Terabe, M., Kapoor, V., ElGindi, M., et al. (2016) · Nature · doi:10.1038/nature16969 · Cited by 766
Self-citation
The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer
Affo, S., Yu, L.-X., & Schwabe, R. F. (2017) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100322 · Cited by 757
The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma
Donné, R., & Lujambio, A. (2022) · Hepatology · doi:10.1002/hep.32740 · Cited by 659
Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor #
Hoechst, B., Voigtlaender, T., Ormandy, L. A., Gamrekelashvili, J., Zhao, F., Wedemeyer, H. H., Lehner, F., Manns, M. P., Greten, T. F., & Korangy, F. (2009) · Hepatology · doi:10.1002/hep.23054 · Cited by 646
Self-citation
Myeloid-derived suppressor cell heterogeneity and subset definition
Peranzoni, E., Zilio, S., Marigo, I., Dolcetti, L., Zanovello, P., Mandruzzato, S., & Bronte, V. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.01.021 · Cited by 634
Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression
Eggert, T., Wolter, K., Ji, J., Ma, C., Yevsa, T., Klotz, S., Medina-Echeverz, J., Longerich, T., Forgues, M., Reisinger, F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.003 · Cited by 609
Self-citation
Myeloid-Derived Suppressor Cells Suppress Antitumor Immune Responses through IDO Expression and Correlate with Lymph Node Metastasis in Patients with Breast Cancer
Yu, J., Du, W., Fang, Y., Wang, Y., Li, H., Cao, S., Yu, W., Shen, C., Liu, J., & Ren, X. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201449 · Cited by 625
Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13
Gabitass, R. F., Annels, N. E., Stocken, D. D., Pandha, H., & Middleton, G. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1028-0 · Cited by 574
Immunological landscape and immunotherapy of hepatocellular carcinoma
Prìeto, J., Melero, I., & Sangro, B. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.173 · Cited by 573
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
Weber, R., Fleming, V., Hu, X., Nagibin, V. S., Groth, C., Altevogt, P., Utikal, J. S., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01310 · Cited by 546
Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells
Obermajer, N., Muthuswamy, R., Lesnock, J. L., Edwards, R. P., & Kaliński, P. (2011) · Blood · doi:10.1182/blood-2011-07-365825 · Cited by 511
Myeloid-Derived Suppressor Cells
Parker, K. H., Beury, D. W., & Ostrand‐Rosenberg, S. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.04.002 · Cited by 490
Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer
Law, A. M. K., Valdes-Mora, F., & Gallego-Ortega, D. (2020) · Cells · doi:10.3390/cells9030561 · Cited by 455
Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma
Chiu, D. K.-C., Tse, A. P.-W., Xu, I. M.-J., Di Cui, J., Lai, R. K.-H., Li, L. L., Koh, H.-Y., Tsang, F. H.-C., Wei, L. L., Wong, C.-M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00530-7 · Cited by 448
Myeloid Cell-Derived Arginase in Cancer Immune Response
Grzywa, T. M., Sosnowska, A., Matryba, P., Rydzyńska, Z., Jasiński, M., Nowis, D., & Gołąb, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00938 · Cited by 446
Myeloid derived suppressor cells in human diseases
Greten, T. F., Manns, M. P., & Korangy, F. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.01.003 · Cited by 398
Self-citation
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans
Görgün, G., Whitehill, G., Anderson, J. L., Hideshima, T., Maguire, C., Laubach, J. P., Raje, N. S., Munshi, N. C., Richardson, P. G. G., & Anderson, K. C. (2013) · Blood · doi:10.1182/blood-2012-08-448548 · Cited by 394
From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma
Fu, Y., Liu, S., Zeng, S., & Shen, H. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1396-4 · Cited by 395
Regulatory T Cells in Cancer
Mougiakakos, D., Choudhury, A., Lladser, Á., Kiessling, R. W., & Johansson, C. C. (2010) · Advances in cancer research · doi:10.1016/s0065-230x(10)07003-x · Cited by 413
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391
Myeloid‐derived suppressor cell heterogeneity in human cancers
Solito, S., Marigo, I., Pinton, L., Damuzzo, V., Mandruzzato, S., & Bronte, V. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12469 · Cited by 395
Immature Immunosuppressive CD14+HLA-DR−/low Cells in Melanoma Patients Are Stat3hi and Overexpress CD80, CD83, and DC-Sign
Poschke, I. C., Mougiakakos, D., Hansson, J., Masucci, G. V., & Kiessling, R. W. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3767 · Cited by 381
Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology
Dumitru, C. A., Moses, K., Trellakis, S., Lang, S., & Brandau, S. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1294-5 · Cited by 370
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment
Llovet, J. M., Willoughby, C. E., Singal, A. G., Greten, T. F., Heikenwälder, M., El-Serag, H. B., Finn, R. S., & Friedman, S. L. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00754-7 · Cited by 354
Self-citation
The Role of Fibrosis and Liver-Associated Fibroblasts in the Pathogenesis of Hepatocellular Carcinoma
Baglieri, J., Brenner, D. A., & Kisseleva, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071723 · Cited by 347
The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion
Cicco, P. D., Ercolano, G., & Ianaro, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01680 · Cited by 341
Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function
Sander, L. E., Sackett, S. D., Dierssen, U., Beraza, N., LINKE, R. P., Müller, M. M., Blander, J. M., Tacke, F., & Trautwein, C. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20091474 · Cited by 346
Clinical recovery from surgery correlates with single-cell immune signatures
Gaudilliere, B. L., Fragiadakis, G. K., Bruggner, R. V., Nicolau, M., Finck, R., Tingle, M. S., Silva, J., Ganio, E. A., Yeh, C. G., Maloney, W. J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009701 · Cited by 339
Hypoxia‐inducible factors in regulation of immune responses in tumour microenvironment
Kumar, V., & Gabrilovich, D. I. (2014) · Immunology · doi:10.1111/imm.12380 · Cited by 329
Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells
Ruf, B., Heinrich, B., & Greten, T. F. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00572-w · Cited by 318
Self-citation
Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties
Brandau, S., Trellakis, S., Bruderek, K., Schmaltz, D., Steller, G., Elian, M., Suttmann, H., Schenck, M., Welling, J., Zabel, P., et al. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0310162 · Cited by 314
IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy
Weber, R., Groth, C., Lasser, S., Arkhypov, I., Petrova, V., Altevogt, P., Utikal, J. S., & Umansky, V. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104254 · Cited by 317
Myeloid-Derived Suppressor Cells in Inflammatory Bowel Disease: A New Immunoregulatory Pathway
Haile, L. A., von Wasielewski, R., Gamrekelashvili, J., Krüger, C., Bachmann, O. P., Westendorf, A. M., Buer, J., Liblau, R., Manns, M. P., Korangy, F., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.032 · Cited by 308
Self-citation
IL4Rα+ Myeloid-Derived Suppressor Cell Expansion in Cancer Patients
Mandruzzato, S., Solito, S., Falisi, E., Francescato, S., Chiarion‐Sileni, V., D, S. M. M., Zanon, A., Rossi, C. R., Nitti, D., Bronte, V., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803831 · Cited by 302
Role of nonresolving inflammation in hepatocellular carcinoma development and progression
Yu, L., Yan, L., & Wang, H. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0048-z · Cited by 309
Direct and Differential Suppression of Myeloid-Derived Suppressor Cell Subsets by Sunitinib Is Compartmentally Constrained
Ko, J. S., Rayman, P. A., Ireland, J. L., Swaidani, S., Li, G., Bunting, K. D., Rini, B. I., Finke, J. H., & Cohen, P. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3278 · Cited by 304
The functional crosstalk between myeloid-derived suppressor cells and regulatory T cells within the immunosuppressive tumor microenvironment
Haist, M., Stege, H., Grabbe, S., & Bros, M. (2021) · Cancers · doi:10.3390/cancers13020210 · Cited by 295
The yin and yang of evasion and immune activation in HCC
Makarova‐Rusher, O. V., Medina‐Echeverz, J., Duffy, A. G., & Greten, T. F. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.038 · Cited by 299
Self-citation
Myeloid-Derived Suppressor Cells in Tumors: From Mechanisms to Antigen Specificity and Microenvironmental Regulation
Yang, Y., Li, C., Liu, T., Dai, X., & Bazhin, A. V. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01371 · Cited by 294
Recent advances on the role of tumor exosomes in immunosuppression and disease progression
Filipazzi, P., Bürdek, M., Villa, A., Rivoltini, L., & Huber, V. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.02.005 · Cited by 287
Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma
Mizukoshi, E., Yamashita, T., Arai, K., Sunagozaka, H., Ueda, T., Arihara, F., Kagaya, T., Yamashita, T., Fushimi, K., & Kaneko, S. (2012) · Hepatology · doi:10.1002/hep.26153 · Cited by 278
Circulating and Tumor-Infiltrating Myeloid-Derived Suppressor Cells in Patients with Colorectal Carcinoma
Zhang, B., Wang, Z., Wu, L., Zhang, M., Li, W., Ding, J., Zhu, J., Wei, H., & Zhao, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057114 · Cited by 286
Current knowledge on psoriasis and autoimmune diseases
McCormick, T. S., Ayala‐Fontanez, N., & Soler, D. C. (2016) · Psoriasis Targets and Therapy · doi:10.2147/ptt.s64950 · Cited by 279
Higher Frequencies of GARP+CTLA-4+Foxp3+ T Regulatory Cells and Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Are Associated with Impaired T-Cell Functionality
Kalathil, S. G., Lugade, A. A., Miller, A., Iyer, R. V., & Thanavala, Y. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3381 · Cited by 276
Immunosuppressive CD14 + HLA‐DR low/− monocytes in prostate cancer
Vuk‐Pavlović, S., Bulur, P. A., Lin, Y., Qin, R., Szumlanski, C. L., Zhao, X., & Dietz, A. B. (2009) · The Prostate · doi:10.1002/pros.21078 · Cited by 265
Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma
Zhang, Q., Ma, C., Duan, Y., Heinrich, B., Rosato, U., Diggs, L. P., Ma, L., Roy, S., Fu, Q., Brown, Z. J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0304 · Cited by 266
Self-citation
Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients
Zhou, J., Ding, T., Pan, W., Zhu, L., Li, L., & Zheng, L. (2009) · International Journal of Cancer · doi:10.1002/ijc.24556 · Cited by 262
Increase in CD14+HLA-DR−/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis
Arihara, F., Mizukoshi, E., Kitahara, M., Takata, Y., Arai, K., Yamashita, T., Nakamoto, Y., & Kaneko, S. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1447-1 · Cited by 254
Increased Myeloid-Derived Suppressor Cells in Gastric Cancer Correlate with Cancer Stage and Plasma S100A8/A9 Proinflammatory Proteins
Wang, L., Chang, E. W. Y., Wong, S. C., Ong, S., Chong, D. Q. Y., & Ling, K. L. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1202088 · Cited by 249
The significance of intertumor and intratumor heterogeneity in liver cancer
Liu, J., Dang, H. T., & Wang, X. W. (2018) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.165 · Cited by 255
Immunosuppressive CD14+HLA-DRlow/− monocytes in B-cell non-Hodgkin lymphoma
Lin, Y., Gustafson, M. P., Bulur, P. A., Gastineau, D. A., Witzig, T. E., & Dietz, A. B. (2011) · Blood · doi:10.1182/blood-2010-05-283820 · Cited by 244
Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients
Filipazzi, P., Huber, V., & Rivoltini, L. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1161-9 · Cited by 247
Emerging immunotherapy for HCC: A guide for hepatologists
Foerster, F., Gairing, S. J., Ilyas, S. I., & Galle, P. R. (2022) · Hepatology · doi:10.1002/hep.32447 · Cited by 245
Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26
Chiu, D. K., Xu, I. M., Lai, R. K., Tse, A. P., Wei, L. L., Koh, H., Li, L. L., Lee, D., Lo, R. C., Wong, C., et al. (2016) · Hepatology · doi:10.1002/hep.28655 · Cited by 241
Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions
Hato, T., Goyal, L., Greten, T. F., Duda, D. G., & Zhu, A. X. (2014) · Hepatology · doi:10.1002/hep.27246 · Cited by 242
Self-citation
Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells
Hoechst, B., Gamrekelashvili, J., Manns, M. P., Greten, T. F., & Korangy, F. (2011) · Blood · doi:10.1182/blood-2010-11-317321 · Cited by 250
Self-citation
Trial watch
Senovilla, L., Vacchelli, E., Galon, J., Adjemian, S., Eggermont, A. M. M., Fridman, W. H., Sautès‐Fridman, C., Ma, Y., Tartour, É., Zitvogel, L., et al. (2012) · OncoImmunology · doi:10.4161/onci.22009 · Cited by 254
Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone
Gustafson, M. P., Lin, Y., New, K. C., Bulur, P. A., O’Neill, B. P., Gastineau, D. A., & Dietz, A. B. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq001 · Cited by 243
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis
Trabanelli, S., Chevalier, M. F., Martínez-Usatorre, A., Gomez‐Cadena, A., Salomé, B., Lecciso, M., Salvestrini, V., Verdeil, G., Racle, J., Papayannidis, C., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00678-2 · Cited by 234
Biomarkers for immunotherapy of hepatocellular carcinoma
Greten, T. F., Villanueva, A., Korangy, F., Ruf, B., Yarchoan, M., Ma, L., Ruppin, E., & Wang, X. W. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00816-4 · Cited by 227
Self-citation
Regulatory myeloid cells paralyze T cells through cell–cell transfer of the metabolite methylglyoxal
Baumann, T., Dunkel, A., Schmid, C., Schmitt, S., Hiltensperger, M., Lohr, K., Laketa, V., Donakonda, S., Ahting, U., Lorenz‐Depiereux, B., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0666-9 · Cited by 230
Myeloid-Derived Suppressor Cells in Human Cancer
Nagaraj, S., & Gabrilovich, D. I. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eb3358 · Cited by 222
Phenotype, development, and biological function of myeloid-derived suppressor cells
Zhao, Y., Wu, T., Shao, S., Shi, B., & Zhao, Y. X. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1004983 · Cited by 220
Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response
Keenan, B. P., Fong, L. H., & Kelley, R. K. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0749-z · Cited by 220
S100A9 a new marker for monocytic human myeloid‐derived suppressor cells
Zhao, F., Hoechst, B., Duffy, A. G., Gamrekelashvili, J., Fioravanti, S., Manns, M. P., Greten, T. F., & Korangy, F. (2012) · Immunology · doi:10.1111/j.1365-2567.2012.03566.x · Cited by 216
Self-citation
Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA-DR−/low Myeloid-Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma
Brimnes, M. K., Vangsted, A. J., Knudsen, L. M., Gimsing, P., Gang, A. O., Johnsen, H. E., & Svane, I. M. (2010) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2010.02463.x · Cited by 218
Combined locoregional-immunotherapy for liver cancer
Greten, T. F., Mauda‐Havakuk, M., Heinrich, B., Korangy, F., & Wood, B. J. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.01.027 · Cited by 211
Self-citation
A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma
Greten, T. F., Forner, A., Korangy, F., Nkontchou, G., Barget, N., Ayuso, C., Ormandy, L. A., Manns, M. P., Beaugrand, M., & Bruix, J. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-209 · Cited by 210
Self-citation
Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer
Panni, R. Z., Sanford, D. E., Belt, B. A., Mitchem, J. B., Worley, L. A., Goetz, B. D., Mukherjee, P., Wang‐Gillam, A., Link, D. C., DeNardo, D. G., et al. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1527-x · Cited by 216
Increased CD14+HLA-DR-/low myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients
Huang, A., Zhang, B., Wang, B., Zhang, F., Fan, K., & Guo, Y. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1450-6 · Cited by 209
Myeloid‐derived suppressor cells in cancer: recent progress and prospects
Khaled, Y. S., Ammori, B. J., & Elkord, E. (2013) · Immunology and Cell Biology · doi:10.1038/icb.2013.29 · Cited by 214
Functional characterization of human Cd33+ And Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines
Lechner, M. G., Megiel, C., Russell, S. M., Bingham, B., Arger, N., Woo, T. T., & Epstein, A. L. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-90 · Cited by 208
Human Tumor-Infiltrating Myeloid Cells: Phenotypic and Functional Diversity
Elliott, L., Doherty, G. A., Sheahan, K. D., & Ryan, E. J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00086 · Cited by 219
Complexity and challenges in defining myeloid-derived suppressor cells
Damuzzo, V., Pinton, L., Desantis, G., Solito, S., Marigo, I., Bronte, V., & Mandruzzato, S. (2014) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21206 · Cited by 218
Neutrophils in cancer
Treffers, L. W., Hiemstra, I. H., Kuijpers, T. W., van den Berg, T. K., & Matlung, H. L. (2016) · Immunological Reviews · doi:10.1111/imr.12444 · Cited by 211
Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy
Zhou, J., Liu, M., Sun, H., Feng, Y., Xu, L., Chan, A. W. H., TONG, J. H. M., Wong, J., Chong, C. C. N., Lai, P. B. S., et al. (2017) · Gut · doi:10.1136/gutjnl-2017-314032 · Cited by 206
Myeloid-derived Suppressor Cells in Cancer Patients
Montero, A. J., Diaz-Montero, C. M., Kyriakopoulos, C. E., Bronte, V., & Mandruzzato, S. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318242169f · Cited by 201
Signaling pathways involved in MDSC regulation
Trikha, P., & Carson, W. E. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.04.003 · Cited by 207
Immune-based therapies for hepatocellular carcinoma
Pinato, D. J., Guerra, N., Fessas, P., Murphy, R., Mineo, T., Mauri, F. A., Mukherjee, S. K., Thursz, M. R., Wong, C. N., Sharma, R., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1249-9 · Cited by 202
Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples
Kotsakis, A. P., Harasymczuk, M., Schilling, B., Georgoulias, V., Argiris, A. E., & Whiteside, T. L. (2012) · Journal of Immunological Methods · doi:10.1016/j.jim.2012.04.004 · Cited by 199
Immunotherapy for hepatocellular carcinoma: Current and future
Johnston, M. P., & Khakoo, S. I. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i24.2977 · Cited by 196
The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications
Hou, J., Zhang, H., Sun, B., & Karin, M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.014 · Cited by 198
Hepatic Stellate Cell-Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis
Matsuda, M., & Seki, E. (2020) · Seminars in Liver Disease · doi:10.1055/s-0040-1708876 · Cited by 189
GM-CSF Promotes the Immunosuppressive Activity of Glioma-Infiltrating Myeloid Cells through Interleukin-4 Receptor-α
Kohanbash, G., McKaveney, K., Sakaki, M., Ueda, R., Mintz, A. H., Amankulor, N. A., Fujita, M., Ohlfest, J. R., & Okada, H. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4124 · Cited by 189
Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells
Deng, Y., Cheng, J., Fu, B., Liu, W., Chen, G., Zhang, Q., & Yang, Y. (2016) · Oncogene · doi:10.1038/onc.2016.273 · Cited by 193
The Liver Is a Site for Tumor-Induced Myeloid-Derived Suppressor Cell Accumulation and Immunosuppression
Ilkovitch, D., & Lopez, D. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4625 · Cited by 187
Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment
Bourhis, M., Palle, J., Galy–Fauroux, I., & Terme, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.616837 · Cited by 192
Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma
Kapanadze, T. G., Gamrekelashvili, J., Ma, C., Chan, C., Zhao, F., Hewitt, S. M., Zender, L., Kapoor, V., Felsher, D. W., Manns, M. P., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.06.010 · Cited by 186
Self-citation
Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer
Idorn, M., Køllgaard, T., Kongsted, P., Sengeløv, L., & Straten, P. T. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1591-2 · Cited by 182
Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion
Lu, J., Luo, Y., Rao, D., Wang, T., Lei, Z., Chen, X., Zhang, B., Li, Y., Liu, B., Xia, L., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00505-7 · Cited by 194
Reciprocal Relationship between Myeloid-Derived Suppressor Cells and T Cells
Nagaraj, S., Youn, J., & Gabrilovich, D. I. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300654 · Cited by 186
Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer
Schneider, C., Teufel, A., Yevsa, T., Staib, F., Hohmeyer, A., Walenda, G., Zimmermann, H. W., Vucur, M., Huss, S., Gaßler, N., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301116 · Cited by 182

Authors: Hoechst, B., Ormandy, L. A., Ballmaier, M., Lehner, F., Krüger, C., Manns, M. P., Greten, T. F., & Korangy, F.
Affiliations: Medizinische Hochschule Hannover (DE)
Corresponding author: Korangy, Firouzeh
ORCID: Ballmaier, Matthias
Lehner, Frank
Manns, Michael P.
Greten, Tim F.
Korangy, Firouzeh
Venue: Gastroenterology
Publisher: Elsevier BV
Published: 2008-07
Volume: 135
Issue: 1
Pages: 234-243
ISSN: 0016-5085 (ISSN-L)
DOI: 10.1053/j.gastro.2008.03.020
OpenAlex: W2059688175
Cited by: 793
References: 31
Citations by year: 2026: 18 · 2025: 20 · 2024: 25 · 2023: 34 · 2022: 50 · 2021: 46 · 2020: 53 · 2019: 40 · 2018: 39 · 2017: 60 · 2016: 54 · 2015: 65 · 2014: 55 · 2013: 65 · 2012: 59
FWCI: 15.02
Type: journal article
Language: en
Update notices: erratum (2011-08-01)
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Gastroenterology (publishedVersion)
PubMed (publishedVersion)
Funders: Deutsche Forschungsgemeinschaft (SFB-738)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords: myeloid-derived suppressor cells, hepatocellular carcinoma, regulatory T cells, immunosuppression, arginase activity, CD4+CD25+Foxp3+ T cells, tumor immune microenvironment, T cell proliferation inhibition, cancer immunotherapy
MeSH terms: Aged, Arginase, Cell Communication, Cell Division, Cells, Cultured, Female, Flow Cytometry, Carcinoma, Hepatocellular, HLA-DR Antigens, Humans, Immune Tolerance, Liver Neoplasms, Male, Middle Aged, Biomarkers, CD4-Positive T-Lymphocytes, CD4 Antigens, Immunophenotyping, Interleukin-10, Lipopolysaccharide Receptors, Myeloid Cells, Forkhead Transcription Factors, Interleukin-2 Receptor alpha Subunit

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4+CD25+Foxp3+ T Cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks